Marc Voigt
Chief Executive Officer at IMMUTEP LIMITED
Net worth: 3 M $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Frédéric Triebel | M | 69 |
Immutep SAS
 Immutep SAS Pharmaceuticals: MajorHealth Technology Immutep SAS specializes in biotechnology research and development. It develops immunotherapy treatments for cancer and autoimmune diseases. The company was founded by Frédéric Triebel on October 17, 2001 and is headquartered Orsay, France. | 23 years |
| Deanne Miller | F | 47 |
Immutep GmbH
 Immutep GmbH BiotechnologyHealth Technology Part of Immutep Ltd., Immutep GmbH develops novel immunotherapy treatments for cancer and autoimmune disease. The private company is based in Leipzig, Germany. The CEOs of the German company are - Kaufmann, Marc Voigt, Deanne Miller. | 12 years |
| Russell Howard | M | 74 | 11 years | |
| Christian Mueller | M | - | 6 years | |
| Pete Meyers | M | 55 | 10 years | |
| Anne Anderson | F | - | - | |
| John B. Hawken | M | 76 |
Immutep SAS
Immutep SAS Pharmaceuticals: MajorHealth Technology Immutep SAS specializes in biotechnology research and development. It develops immunotherapy treatments for cancer and autoimmune diseases. The company was founded by Frédéric Triebel on October 17, 2001 and is headquartered Orsay, France. | 21 years |
| Luc St-Onge | M | 58 |
Pharma-Lizenz-Club Deutschland
| - |
| Bernd Mühlenweg | M | 52 |
Pharma-Lizenz-Club Deutschland
| - |
| Heiner Pieper | M | - |
Pharma-Lizenz-Club Deutschland
| - |
| Irina Staatz-Granzer | M | 64 |
Pharma-Lizenz-Club Deutschland
| - |
| David Fang | M | - | 6 years | |
| Kaufmann | M | - |
Immutep GmbH
Immutep GmbH BiotechnologyHealth Technology Part of Immutep Ltd., Immutep GmbH develops novel immunotherapy treatments for cancer and autoimmune disease. The private company is based in Leipzig, Germany. The CEOs of the German company are - Kaufmann, Marc Voigt, Deanne Miller. | - |
| Frank Fliegert | M | - | - | |
| Christian Toloczyki | M | - | - | |
| Claudia Jacoby | F | - | - | |
| Lis Boyce | F | - | 1 years | |
| Florian Vogl | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Lucinda Hughes Turnbull | F | 66 | 9 years | |
| Martin Frederick Rogers | M | 43 | 6 years | |
| Matthew B. Lehman | M | 47 | 4 years | |
| Yue-Ling Wong | M | 65 | 7 years | |
| Truc Le | M | - | 4 years | |
| Richard J. Hammel | M | 81 | 9 years | |
| Grant Chamberlain | M | 53 | 5 years | |
| Phillip Hains | M | 64 | 9 years | |
| Ian Edward Bangs | M | 70 | 1 years | |
| Ginny Raymond | F | - | 2 years | |
| Stuart Roberts | M | - | - | |
| Gerhard Wolff | M | - |
Revotar Biopharmaceuticals AG
 Revotar Biopharmaceuticals AG Pharmaceuticals: MajorHealth Technology Revotar Biopharmaceuticals AG specializes in the research and development of anti-inflammatory drugs. The firm develops drugs for the therapy and treatment of inflammatory disorders such as psoriasis, asthma and acute lung injuries, and chronic obstructive pulmonary diseases. Its focus areas include product licensing, drug discovery, and clinical development. The firm also engages in partnerships and projects with biotechnology research institutions and pharmaceutical enterprises. The company was founded in August 2000 and is headquartered in Hennigsdorf, Germany. | - |
| Larisa Chisholm | F | - | 14 years | |
| Marta Schilling | F | - | - | |
| Rafi Kazandjian | M | - |
Immutep SAS
Immutep SAS Pharmaceuticals: MajorHealth Technology Immutep SAS specializes in biotechnology research and development. It develops immunotherapy treatments for cancer and autoimmune diseases. The company was founded by Frédéric Triebel on October 17, 2001 and is headquartered Orsay, France. | - |
| Jessica Brown | F | - | - | |
| Tom Bloomfield | M | - | - | |
| Jay R. Campbell | M | - | - | |
| Indira Naidu | F | - | - | |
| Michel Gréco | M | 80 |
Immutep SAS
Immutep SAS Pharmaceuticals: MajorHealth Technology Immutep SAS specializes in biotechnology research and development. It develops immunotherapy treatments for cancer and autoimmune diseases. The company was founded by Frédéric Triebel on October 17, 2001 and is headquartered Orsay, France. | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Australia | 29 | 76.32% |
| Germany | 7 | 18.42% |
| France | 4 | 10.53% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Marc Voigt
- Personal Network
